The Disease – Equine Herpesvirus

- EHV-1 and EHV-4 are transmitted by aerosol or by direct contact with nasal secretions
- EHV-4 causes primarily respiratory disease
  - 80 – 85% of EHV respiratory disease caused by EHV-4
  - More common in younger horses
- EHV-1 is the more virulent equine herpesvirus and is capable of producing abortion, respiratory disease, stillbirths, perinatal foal death and neurologic disease in infected animals
- EHV-1 replicates in the respiratory epithelium
  - Localizes in respiratory tract lymph nodes within 2 – 3 days of infection
- EHV-1 is shed in nasal secretions (viral shedding) in large quantities during the first days of infection and quickly becomes intracellular. It persists in white blood cells for days or even weeks
- EHV-1 initially enters the body through the respiratory mucosa and invades the respiratory tract
  - EHV-1 may also infect endothelial cells of the fetus and/or the endometrium and placenta in pregnant mares, and of small blood vessels in the nose, lungs, brain and spinal cord, as well as circulating leukocytes, which carry the virus to other parts of the body where it can cause abortion or neurologic disease
  - EHV-1 induces lifelong latent infection in the majority of exposed horses
    - Establishes latency in cytotoxic T lymphocytes, local lymph nodes and trigeminal ganglion
    - Recrudescence of EHV-1 may cause clinical signs of respiratory disease, abortion and cell-associated (CTL) viremia and nasal shedding

Management & Prevention

- Reduce nasal discharge and viral shedding
- Reduce dissemination of virus within the infected horse
  - Neutralize free virus (VN antibody titers) at mucosal surface and free virus circulating in the blood
  - Stimulate production/activation of cytotoxic lymphocytes (CTL) in order to lyse virus infected cells in the upper respiratory tract (URT) and in lymphocytes
- EHV vaccines are currently labeled as an aid in the prevention of abortion or respiratory disease associated with EHV infection
  - No EHV vaccine is labeled for prevention of neurologic disease

Contact your Merck Animal Health or distributor sales representative to learn more.
In a severe EHV-1 challenge study, Prestige® Prodigy®-vaccinated mares demonstrated a 96.1% reduction in virus shedding from nasal exudates.

In an independent research study, Prestige® Prodigy® produced a statistically significant EHV-1 antibody response (VN antibody titers).

In an independent research study, Prestige® Prodigy® produced a statistically significant IFN-γ response. This cytokine, i.e., IFN-γ response, can be a useful surrogate for quantifying cytotoxic lymphocyte responses, shown to be a measure of cell-mediated protective immunity (CMI) to EHV-1 infection.

Conclusion
Prestige® Prodigy® reduces nasal discharge and virus shedding, produces a superior VN antibody response and stimulates a cell-mediated immune (CMI) response, suggesting that it generates a comprehensive immune response for protection from EHV-1 respiratory infection.

1 Intervet Research Data